Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
Identifieur interne : 000388 ( Main/Exploration ); précédent : 000387; suivant : 000389Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
Auteurs : Valérie Künzi [Suisse] ; Martin Dornseiff ; Jörg Horwath ; Katharina HartmannSource :
- Vaccine [ 0264-410X ] ; 2009.
Descripteurs français
- KwdFr :
- Allemagne, Enfant, Enfant d'âge préscolaire, Enquêtes et questionnaires, Humains, Nourrisson, Surveillance post-commercialisation des produits de santé, Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins à virosomes (effets indésirables), Vaccins à virosomes (immunologie).
- MESH :
- effets indésirables : Vaccins antigrippaux, Vaccins à virosomes.
- immunologie : Vaccins antigrippaux, Vaccins à virosomes.
- Allemagne, Enfant, Enfant d'âge préscolaire, Enquêtes et questionnaires, Humains, Nourrisson, Surveillance post-commercialisation des produits de santé.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Influenza Vaccines, Vaccines, Virosome.
- chemical , immunology : Influenza Vaccines, Vaccines, Virosome.
- geographic : Germany.
- Child, Child, Preschool, Humans, Infant, Product Surveillance, Postmarketing, Surveys and Questionnaires.
Abstract
A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.
DOI: 10.1016/j.vaccine.2008.12.008
PubMed: 19114080
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safe vaccination of children with a virosomal adjuvanted influenza vaccine.</title>
<author><name sortKey="Kunzi, Valerie" sort="Kunzi, Valerie" uniqKey="Kunzi V" first="Valérie" last="Künzi">Valérie Künzi</name>
<affiliation wicri:level="1"><nlm:affiliation>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne, Switzerland. valerie.kuenzi@crucell.ch</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne</wicri:regionArea>
<placeName><settlement type="city">Berne</settlement>
<region type="région" nuts="3">Canton de Berne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dornseiff, Martin" sort="Dornseiff, Martin" uniqKey="Dornseiff M" first="Martin" last="Dornseiff">Martin Dornseiff</name>
</author>
<author><name sortKey="Horwath, Jorg" sort="Horwath, Jorg" uniqKey="Horwath J" first="Jörg" last="Horwath">Jörg Horwath</name>
</author>
<author><name sortKey="Hartmann, Katharina" sort="Hartmann, Katharina" uniqKey="Hartmann K" first="Katharina" last="Hartmann">Katharina Hartmann</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19114080</idno>
<idno type="pmid">19114080</idno>
<idno type="doi">10.1016/j.vaccine.2008.12.008</idno>
<idno type="wicri:Area/Main/Corpus">000427</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000427</idno>
<idno type="wicri:Area/Main/Curation">000427</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000427</idno>
<idno type="wicri:Area/Main/Exploration">000427</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Safe vaccination of children with a virosomal adjuvanted influenza vaccine.</title>
<author><name sortKey="Kunzi, Valerie" sort="Kunzi, Valerie" uniqKey="Kunzi V" first="Valérie" last="Künzi">Valérie Künzi</name>
<affiliation wicri:level="1"><nlm:affiliation>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne, Switzerland. valerie.kuenzi@crucell.ch</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne</wicri:regionArea>
<placeName><settlement type="city">Berne</settlement>
<region type="région" nuts="3">Canton de Berne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dornseiff, Martin" sort="Dornseiff, Martin" uniqKey="Dornseiff M" first="Martin" last="Dornseiff">Martin Dornseiff</name>
</author>
<author><name sortKey="Horwath, Jorg" sort="Horwath, Jorg" uniqKey="Horwath J" first="Jörg" last="Horwath">Jörg Horwath</name>
</author>
<author><name sortKey="Hartmann, Katharina" sort="Hartmann, Katharina" uniqKey="Hartmann K" first="Katharina" last="Hartmann">Katharina Hartmann</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child</term>
<term>Child, Preschool</term>
<term>Germany</term>
<term>Humans</term>
<term>Infant</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Product Surveillance, Postmarketing</term>
<term>Surveys and Questionnaires</term>
<term>Vaccines, Virosome (adverse effects)</term>
<term>Vaccines, Virosome (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Enquêtes et questionnaires</term>
<term>Humains</term>
<term>Nourrisson</term>
<term>Surveillance post-commercialisation des produits de santé</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins à virosomes (effets indésirables)</term>
<term>Vaccins à virosomes (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Virosome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Virosome</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins à virosomes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins à virosomes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child</term>
<term>Child, Preschool</term>
<term>Humans</term>
<term>Infant</term>
<term>Product Surveillance, Postmarketing</term>
<term>Surveys and Questionnaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Enquêtes et questionnaires</term>
<term>Humains</term>
<term>Nourrisson</term>
<term>Surveillance post-commercialisation des produits de santé</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19114080</PMID>
<DateCompleted><Year>2009</Year>
<Month>04</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>27</Volume>
<Issue>8</Issue>
<PubDate><Year>2009</Year>
<Month>Feb</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Safe vaccination of children with a virosomal adjuvanted influenza vaccine.</ArticleTitle>
<Pagination><MedlinePgn>1261-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2008.12.008</ELocationID>
<Abstract><AbstractText>A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Künzi</LastName>
<ForeName>Valérie</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Crucell, Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne, Switzerland. valerie.kuenzi@crucell.ch</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dornseiff</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Horwath</LastName>
<ForeName>Jörg</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hartmann</LastName>
<ForeName>Katharina</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>12</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C475022">Inflexal V</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022721">Vaccines, Virosome</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022721" MajorTopicYN="N">Vaccines, Virosome</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>07</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>11</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>12</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>12</Month>
<Day>31</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>12</Month>
<Day>31</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>4</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19114080</ArticleId>
<ArticleId IdType="pii">S0264-410X(08)01729-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2008.12.008</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suisse</li>
</country>
<region><li>Canton de Berne</li>
</region>
<settlement><li>Berne</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Dornseiff, Martin" sort="Dornseiff, Martin" uniqKey="Dornseiff M" first="Martin" last="Dornseiff">Martin Dornseiff</name>
<name sortKey="Hartmann, Katharina" sort="Hartmann, Katharina" uniqKey="Hartmann K" first="Katharina" last="Hartmann">Katharina Hartmann</name>
<name sortKey="Horwath, Jorg" sort="Horwath, Jorg" uniqKey="Horwath J" first="Jörg" last="Horwath">Jörg Horwath</name>
</noCountry>
<country name="Suisse"><region name="Canton de Berne"><name sortKey="Kunzi, Valerie" sort="Kunzi, Valerie" uniqKey="Kunzi V" first="Valérie" last="Künzi">Valérie Künzi</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000388 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000388 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= GrippeAllemagneV3 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:19114080 |texte= Safe vaccination of children with a virosomal adjuvanted influenza vaccine. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19114080" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a GrippeAllemagneV3
This area was generated with Dilib version V0.6.35. |